Clinical Trial: Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease.

Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Rate of Alpha-synuclein in Cerebrospinal Fluid to Differentiate Patient With Alzheimer's Disease From Those With Lewy Body Disease.

Brief Summary:

Patients with memory disorders are experiencing different trends which are difficult to predict. Moreover, the distinction between Lewy body disease and Alzheimer's disease is not easy as both diseases can present similar symptoms. Nowadays, routine examinations exist and can improve the diagnosis but there are not specific enough of one of those two pathologies.

Lewy body disease is characterized by the presence of particular structures in patient's brain, called "Lewy body", composed of a protein called "alpha-synuclein". The aim of this study is to measure the rate of alpha-synuclein in cerebrospinal fluid. This measurement could allow us to differentiate patient with Alzheimer's disease from those with Lewy body disease.

Detailed Summary:
Sponsor: University Hospital, Strasbourg, France

Current Primary Outcome: rate of alpha-synuclein in cerebrospinal fluid [ Time Frame: Day one. ]

Original Primary Outcome: rate of alpha-synuclein in cerebrospinal fluid [ Time Frame: one time at inclusion ]

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University Hospital, Strasbourg, France

Dates:
Date Received: June 10, 2013
Date Started: April 2013
Date Completion: April 2015
Last Updated: June 17, 2013
Last Verified: June 2013